{
  "pmid": "41392523",
  "title": "Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk.",
  "abstract": "The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase (MMP)-7, and serum anti-malondialdehyde-acetaldehyde (anti-MAA) antibody for RA-associated interstitial lung disease risk stratification. Using a multicenter cohort of US veterans with RA, we performed a cross-sectional study of prevalent RA-ILD and cohort study of incident RA-ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three biomarker score (range 0-3) was calculated based on the presence of MUC5B variant and elevations (upper 25% vs lower 75%) in MMP-7 and anti-MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male, mean age 63.6 years). The odds of prevalent RA-ILD were higher with increased biomarker score (aOR 12.21 [3.82, 38.97] for score of 3 vs. 0). A score â‰¥1 had 76.1% sensitivity, but 48.6% specificity. Incident RA-ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (aHR 4.36 [1.55, 12.27]). Area under the curve for prevalent RA-ILD and Harrel's C for incident RA-ILD were highest when clinical risk factors were combined with the biomarker score. This three-analyte biomarker score was associated with both prevalent and incident RA-ILD, improving risk stratification beyond clinical risk factors. While this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA-ILD risk stratification.",
  "disease": "rheumatoid arthritis"
}